FRE.DE - Fresenius SE & Co. KGaA

XETRA - XETRA Delayed Price. Currency in EUR
43.52
-1.18 (-2.64%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close44.70
Open44.14
Bid43.24 x 120700
Ask43.26 x 6100
Day's Range43.14 - 44.30
52 Week Range24.25 - 51.54
Volume1,734,642
Avg. Volume1,881,983
Market Cap28.841B
Beta (5Y Monthly)1.17
PE Ratio (TTM)12.84
EPS (TTM)3.39
Earnings DateJul 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 21, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      U.S. demand outstripping supply of steroid treatment for COVID

      Soaring hospital demand for the steroid dexamethasone, which British researchers say significantly reduces mortality among severely ill COVID-19 patients, is outstripping supply of the drug, but hospitals have so far been able to treat patients out of their inventories, according to Vizient Inc, a drug buyer for about half of U.S. hospitals. Hospitals and other health-care customers advised by Vizient increased orders of the drug by more than 600% after the researchers announced their findings last week. "What we're hearing from our members is that they are able to treat the patients who do require dexamethasone - they are treating them and they have product," Steven Lucio, vice president of pharmacy solutions at Vizient, said in an interview.

    • Thomson Reuters StreetEvents

      Edited Transcript of FRE.DE earnings conference call or presentation 6-May-20 11:30am GMT

      Q1 2020 Fresenius SE & Co KGaA Earnings Call

    • WeWork Board Factions Head for Clash Over New Directors
      Bloomberg

      WeWork Board Factions Head for Clash Over New Directors

      (Bloomberg) -- WeWork’s board is scheduled to vote on appointing two new directors on Friday, a critical step in a clash between shareholder SoftBank Group Corp. and a rival faction at the troubled co-working startup.A lawyer for WeWork told Delaware Chancery Court Judge Andre Bouchard in a letter that the company plans a May 29 meeting to fill two empty independent director seats. The nominees are Alex Dimitrief, General Electric Co.’s ex-top lawyer, and Frederick Arnold, the former chief financial officer for Convergex Group.SoftBank and the rival board faction are feuding over the Japanese conglomerate’s decision to scrap a $3 billion deal to buy stock from WeWork’s former Chief Executive Officer Adam Neumann and other shareholders. SoftBank agreed to the purchase last year as it bailed out the struggling startup, but then notified stockholders in March that some of the deal’s conditions hadn’t been met.Two independent WeWork directors then sued SoftBank for not following through on the transaction. One of them, Bruce Dunlevie, is a partner at the venture firm Benchmark Capital, which had planned on selling WeWork shares to SoftBank as part of the agreement.The new directors, who are expected to butt heads with the pair who filed the suit, will be on a special board committee tasked with deciding whether Dunlevie and another board member, Lew Frankfort, can properly represent the company in the SoftBank suit.In a court hearing Wednesday, Bouchard rejected bids by Dunlevie and Frankfort to block WeWork from adding new directors. Dunlevie and Frankfort were the only members of the earlier special committee that made the decision to sue. They had sought a so-called “status quo” order to maintain the company’s operations during the SoftBank litigation.“We believe SoftBank has no basis to question the special committee’s authority to bring this action and we are pleased by the court’s recognition that any effort by SoftBank to challenge that authority must be presented” to Bouchard, a spokesman for Dunlevie and Frankfort said Wednesday.SoftBank-backed WeWork officials said they are acting in the best interest of the company.“WeWork is pursuing best practices of corporate governance to determine what role if any WeWork should have in this contractual dispute among its shareholders,” Sarah Lubman, a SoftBank spokeswoman, said in an emailed statement. “The court’s decision today allows that process to go forward.”In their suit, Dunlevie and Frankfort contend SoftBank had “buyer’s remorse” and reneged on promises to “use its reasonable best efforts to consummate” the stock-purchase agreement.They also noted the agreement doesn’t contain a so-called “material adverse effect” provision or similar termination right that is common in such deals. Two years ago, a Delaware judge found such a provision permitted Germany’s Fresenius SE to walk away from its takeover of U.S. rival generic drugmaker Akorn Inc.In a message to shareholders in March, Softbank cited nearly a half-dozen conditions for the deal that WeWork officials hadn’t met, including a failure to renegotiate some leases in the wake of the economic havoc caused by the Covid-19 pandemic.Neumann -- who would have reaped the biggest windfall from the deal -- filed his own suit earlier this month claiming SoftBank is relying on legally faulty pretexts to scuttle the deal.The dispute is among several busted-deal cases tied to Covid-19 that landed in Delaware’s business court. The state is the corporate home to more than half of U.S. public companies and more than 60% of Fortune 500 firms. Chancery judges hear cases without juries and can’t award punitive damages.Dunlevie’s and Frankfort’s suit is The We Company v. SoftBank Group Corp, No. 2020-0258, Delaware Chancery Court (Wilmington). Neumann’s case is Neumann v. SoftBank Group Corp, Delaware Chancery Court.(Updates with judge’s denial of status-quo order in sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    • TheStreet.com

      Akorn Files Chapter 11 After Failure to Be Acquired

      Generic-drug maker Akorn filed a Chapter 11 petition. A deal with its lenders will enable it to continue a search for a buyer.

    • Reuters

      Forescout sues Advent to complete $1.9 billion merger

      Forescout Technologies Inc sued Advent International Corp on Wednesday, after the private equity firm pulled out of a deal to buy the U.S. cybersecurity company for $1.9 billion. Forescout asked the Delaware Court of Chancery to force Advent to complete the deal after the buyout firm notified it last Friday it would back out. In a statement, Advent responded that it had informed Forescout of the company's failure to maintain operations and financial resources as required under the agreement.

    • Results: Fresenius SE & Co. KGaA Beat Earnings Expectations And Analysts Now Have New Forecasts
      Simply Wall St.

      Results: Fresenius SE & Co. KGaA Beat Earnings Expectations And Analysts Now Have New Forecasts

      Fresenius SE & Co. KGaA (ETR:FRE) defied analyst predictions to release its quarterly results, which were ahead of...

    • Fresenius reports first-quarter net income beat on pandemic demand
      Reuters

      Fresenius reports first-quarter net income beat on pandemic demand

      Healthcare companies worldwide have benefited from subsidies and increased demand as a result of the coronavirus crisis, but they have also faced new costs, including protective gear. Fresenius' first-quarter net income was 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, a Refinitiv poll found. "It is, however, too early to say with any certainty what impact COVID-19 will have on the company's full business year," Chief Executive Stephan Sturm said in a statement.

    • Is Fresenius (FMS) a Great Value Stock Right Now?
      Zacks

      Is Fresenius (FMS) a Great Value Stock Right Now?

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

    • Moody's

      Fresenius Finance Ireland II Plc -- Moody's announces completion of a periodic review of ratings of Fresenius SE & Co. KGaA

      Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.

    • Should You Like Fresenius SE & Co. KGaA’s (ETR:FRE) High Return On Capital Employed?
      Simply Wall St.

      Should You Like Fresenius SE & Co. KGaA’s (ETR:FRE) High Return On Capital Employed?

      Today we'll evaluate Fresenius SE & Co. KGaA (ETR:FRE) to determine whether it could have potential as an investment...

    • WeWork Directors Sue SoftBank Over Decision to Abandon Deal
      Bloomberg

      WeWork Directors Sue SoftBank Over Decision to Abandon Deal

      (Bloomberg) -- Two independent WeWork directors sued SoftBank Group Corp., its biggest shareholder, after the Japanese investor scrapped a $3 billion deal to buy stock from ex-Chief Executive Officer Adam Neumann and other shareholders to bail out the struggling workplace provider.SoftBank reneged on promises to “use its reasonable best efforts to consummate” the stock-purchase agreement because of “buyer’s remorse,” the directors, which make up a special committee of WeWork’s board, said in the Delaware Chancery Court lawsuit.“Instead of abiding by its contractual obligations, SoftBank, under increasing pressure from activist investors, has engaged in a purposeful campaign to avoid completion of the tender offer,” said Bruce Dunlevie and Lew Frankfort, who make up the committee. The pair regret “the fact SoftBank continues to put its own interests ahead of those of WeWork’s minority stockholders,” according to an emailed statement.A spokesperson for SoftBank said it would vigorously defend the lawsuit. “Nothing in the special committee’s filing today credibly refutes SoftBank’s decision to terminate the tender offer,” the spokesperson said Tuesday in a statement. Softbank said several conditions for completing the tender were not met and called the special committee’s filing a “desperate and misguided attempt” to revise history.“The Special Committee will not prevail in this mistaken attempt to force SoftBank to purchase their shares when it is not legally obligated to do so,” the spokesperson said.Paul Singer’s Elliott Management Corp., a major investor in Softbank, has advocated for the Japanese company to boost its own value by engaging in stock buybacks.Bailout PackageSoftBank agreed to buy shares from Neumann, Benchmark Capital and others as part of a bailout package last year, but notified stockholders in mid-March that some of the deal’s conditions hadn’t been met. After the deal’s closing deadline passed last week, SoftBank confirmed it was pulling the offer.In a message to shareholders last month, Softbank cited nearly a half-dozen conditions that WeWork officials hadn’t met as the basis for pulling out of purchase, including its failure to renegotiate some leases in the wake of the economic havoc caused by the Covid-19 pandemic. Of the tender offer, $450 million is currently allocated to current and former employees, according to a person with knowledge of the matter.The directors pointed to efforts by SoftBank executives to “thwart” a consolidation of WeWork’s Chinese joint venture as evidence that they had second thoughts about the deal. Softbank cited the failure to complete the “roll-up” of the China unit as one of the conditions that hadn’t been met, while WeWork executives accused their erstwhile partner of creating a pretext for pulling out of the agreement.Softbank’s argument that WeWork failed to gain the necessary regulatory approvals for the deal also doesn’t fly because the only country left to sign off on the transaction was Mexico and WeWork has until August to gain that country’s okay, according to the suit.“SoftBank’s apparent buyer’s remorse” was spurred by its own declining financial condition, the WeWork directors said in the suit. “SoftBank’s enormous and growing debt burden, which is now over $109 billion, led Moody’s to issue a rare two-notch downgrade in SoftBank’s debt rating in March 2020,” according to the suit.‘Material Adverse Effect’The directors also noted the agreement doesn’t contain a so-called “material adverse effect” provision or similar termination right that is common in such deals. Two years ago, a Delaware judge found such a provision permitted Germany’s Fresenius SE to walk away from its takeover of U.S. rival generic drugmaker Akorn Inc.The WeWork directors want a chancery judge to order Softbank to carry out the stock purchase and acknowledge it trampled on the rights of some investors in the workplace provider. “SoftBank’s actions harmed the company’s minority stockholders by depriving them of liquidity, which was the primary consideration they were to receive under” the agreement, the suit said.The suit was filed in Delaware because it’s the corporate home to WeWork and more than half of U.S. public companies.The case is The We Company v. Softbank Group Corp, No. 2020-0258, Delaware Chancery Court (Wilmington)(Adds comment from Softbank in fourth and fifth paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    • Reuters

      Italy looks to safeguard biomedical valley leading fight against COVID-19

      Italy plans to tighten health checks to ensure that work is not disrupted in a small northern town specialising in the production of medical supplies to tackle its coronavirus crisis. The area snuggled around the medieval town of Mirandola has become a focus for desperate health authorities seeking to source equipment in the European country where COVID-19 has taken the most deadly toll. "This is a key strategic sector that we need to nurture and we're going to make sure it stays open for business," said Sergio Venturi, coronavirus czar for the northern region of Emilia Romagna where Mirandola is located.

    • Reuters

      Bed Bath sues 1-800-Flowers for trying to renege on deal over COVID-19

      Bed Bath & Beyond Inc has asked a judge to hold 1-800-Flowers.Com Inc to a $252 million deal between the companies in what appears to one of the first examples of a corporate sale coming unraveled due to the coronavirus pandemic. Bed Bath said in its complaint, filed in Delaware's Court of Chancery, that 1-800-Flowers told it on March 24 the COVID-19 outbreak, the disease caused by the coronavirus, denied the company the resources to close the deal and integrate the business. "Even a calamitous event such as COVID-19 does not permit a party to avoid its obligations," the lawsuit said.

    • Reuters

      EU will avoid medicine shortage, industry chief says

      European Union countries will have access to the medicines they need to care for coronavirus sufferers, the bloc's industry chief Thierry Breton said on Thursday, adding pharmaceutical companies were doubling production to address shortages. The coronavirus pandemic has placed a huge strain on hospitals in Italy, Spain, France, and elsewhere in Europe as intensive care units fill up with tens of thousands of patients suffering the same illness. Hospital executives and doctors of nine European countries said in an open letter on Wednesday they only had up to two weeks worth of supplies of some medicines and urged greater European collaboration.

    • What Is Fresenius SE KGaA's (ETR:FRE) P/E Ratio After Its Share Price Tanked?
      Simply Wall St.

      What Is Fresenius SE KGaA's (ETR:FRE) P/E Ratio After Its Share Price Tanked?

      To the annoyance of some shareholders, Fresenius SE KGaA (ETR:FRE) shares are down a considerable 35% in the last...

    • Thomson Reuters StreetEvents

      Edited Transcript of FRE.DE earnings conference call or presentation 20-Feb-20 12:30pm GMT

      Full Year 2019 Fresenius SE & Co KGaA Earnings Call

    • Fresenius SE & Co. KGaA Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
      Simply Wall St.

      Fresenius SE & Co. KGaA Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

      It's been a good week for Fresenius SE & Co. KGaA (ETR:FRE) shareholders, because the company has just released its...

    • Bingeing Alone Isn’t Enough for Nestle
      Bloomberg

      Bingeing Alone Isn’t Enough for Nestle

      (Bloomberg Opinion) -- It isn’t just Unilever NV that’s struggling to sell more food. Rival Nestle SA now expects to come up short of its self-imposed sales-growth target this year, and it’s counting on acquisitions to put it back on track.While Chief Executive Officer Mark Schneider met the lower end of  a goal for underlying operating margin 12 months early, it will take at least another year for the owner of the Nesquik and Nespresso brands to reach and sustain its annual sales growth objective of 4-6%, partly due to the effect of disposals.It’s a rare misstep for Nestle’s first external CEO for almost 100 years. Even with the 2% drop on Thursday, the shares are up more than 40% since his arrival in January 2017, outpacing Unilever. While Schneider’s made a good start selling off underperformers and making purchases in faster growing areas, such as coffee, pet food and meat substitutes, more reshaping is needed. He has traded — either acquired or moved  out of — businesses that accounted for about 12% of total sales in 2017. That’s ahead of his target for changing up 10% by the end of 2020. He’s not done yet. From here the focus will be more on acquisitions than disposals.While expanding in the right growth markets is key, Schneider should also go further in pruning the Swiss food giant. Possible culprits for offloading could be parts of the U.S. frozen foods business, especially pizzas, or some water assets, such as those mainstream brands that can’t be taken up market. The fact that Nestle wrote down the value of its Yinlu business in China could be a prelude to an exit from difficult divisions, for example making peanut milk. However, selling off these businesses may be trickier than previous disposals in confectionery, skincare and ice cream.There’s also a risk that Schneider, in an effort to turbocharge growth, becomes less disciplined when he buys. He indicated that he’s open to a wide array of options, the most promising being small or mid-sized purchases, particularly in the hot market for nutrition and metabolism. He lamented that last year was heavy on disposals, but light on purchases. That should change this year, but he shouldn’t be too eager and so strike rash deals.Schneider is comfortable in the pharmaceutical space, having led German healthcare company Fresenius SE before joining Nestle. Medical nutrition not only has higher growth prospects and margins than many food areas, but it is also less constrained by competition rules because Nestle doesn’t have such a big position. He most recently bolstered Nestle’s medical nutrition arm by acquiring gastrointestinal medication Zenpep and increased the investment in Aimmune Therapeutics Inc., which has developed a product to counter the effects of peanut allergies. It indicates that this area, particularly treatments related to the body’s metabolism, is likely to be a bigger focus.To fund any large-scale ambitions, Schneider has Nestle’s stake in L’Oreal SA, worth about 35 billion euros ($38 billion), to play with. The company has always said that it won’t part with this holding unless it has a strategic use for the proceeds, but but he seemed to be more open to an exit on Thursday. Small- to medium-sized deals wouldn’t require any change. A bigger transaction — which can’t be ruled out — might.Either way, Schneider can’t afford to take the wrong turn. Not only is activist Dan Loeb still on the register, but Nestle’s valuation has increased significantly under his tenure. The shares trade on about 22 times forward earnings, compared with about 20 times for Unilever.The premium is justified by Unilever’s recent sales stumble, as well as its slower pace of portfolio change and less focused approach to acquisitions. That doesn’t mean Nestle won’t be punished if it disappoints in the same way as its rival.To contact the author of this story: Andrea Felsted at afelsted@bloomberg.netTo contact the editor responsible for this story: Melissa Pozsgay at mpozsgay@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    • Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?
      Simply Wall St.

      Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

      Let's talk about the popular Fresenius SE & Co. KGaA (ETR:FRE). The company's shares saw a double-digit share price...

    • If You Had Bought Fresenius SE KGaA (ETR:FRE) Stock Three Years Ago, You'd Be Sitting On A 34% Loss, Today
      Simply Wall St.

      If You Had Bought Fresenius SE KGaA (ETR:FRE) Stock Three Years Ago, You'd Be Sitting On A 34% Loss, Today

      While not a mind-blowing move, it is good to see that the Fresenius SE & Co. KGaA (ETR:FRE) share price has gained 20...

    • Benzinga

      Highlights From The Deutsche Bank ADR Virtual Investor Conference

      Nine international companies recently made their pitch to investors at the Deutsche Bank Depositary Receipts Virtual Investor Conference, held in conjunction with OTC Markets November 13-14. Heineken’s big initiative, according to Investor Relations Director Federico Castillo, is continuing its global diversification and limiting reliance on individual markets. Today, Heineken owns over 160 breweries in over 70 countries.

    • Does Fresenius SE & Co. KGaA (ETR:FRE) Have A Good P/E Ratio?
      Simply Wall St.

      Does Fresenius SE & Co. KGaA (ETR:FRE) Have A Good P/E Ratio?

      This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

    • Should You Be Pleased About The CEO Pay At Fresenius SE & Co. KGaA's (ETR:FRE)
      Simply Wall St.

      Should You Be Pleased About The CEO Pay At Fresenius SE & Co. KGaA's (ETR:FRE)

      Stephan Sturm has been the CEO of Fresenius SE & Co. KGaA (ETR:FRE) since 2016. First, this article will compare CEO...

    • Thomson Reuters StreetEvents

      Edited Transcript of FRE.DE earnings conference call or presentation 29-Oct-19 12:30pm GMT

      Q3 2019 Fresenius SE & Co KGaA Earnings Call

    • Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments
      Reuters

      Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

      The group said both Fresenius Medical Care <FMEG.DE>, the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Shares in both Fresenius and Fresenius Medical Care were up about 4% in early trade on Tuesday. Analysts said investors were relieved that a summer slowdown at Helios and a further negative impact from a U.S. dialysis treatment coordination programme known as ESCO did not materialize.